ECM Weekly (31st October 2021) - Patym, PolicyBazaar, Nykaa, HeMo, Clover Bio, UJU, Airdoc, Mitratel
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
394 Views
Clover Biopharmaceuticals IPO: Forecasts and Valuation
Clover plans to raise US$236.4m at the midpoint of the IPO price range, and we believe Clover's IPO is attractively priced and expect an upside of...
427 Views
Clover Biopharmaceuticals IPO: Valuation Insights
Clover has launched an IPO to raise net proceeds of $236m at the mid-point of the price range of HK$12.80-13.50 per share. Our valuation analysis...
337 Views
Clover (三叶草生物) IPO: Valuation with a Margin of Safety
We provide an update for the Clover Pharmaceuticals' book building. We think its valuation provides a margin of safety against our conservative...
369 Views
Clover (三叶草生物) Pre-IPO: Thoughts on Valuation
We provide our forecast for its SCB-2019 and SCB-313. The company's valuation is largely anchored on the sales of its COVID-19 vaccine thought SCB...
427 Views